Scancell
Scancell is a pre-revenue, UK-listed clinical-stage immuno-oncology company developing off-the-shelf active cancer immunotherapies (DNA, peptide, and antibody platforms) led by iSCIB1+ for advanced melanoma, licensed to Genmab on its antibody platform and advancing toward a global Phase 3.
- Company typePublic
- Founded1996
- HeadquartersNottingham, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Scancell does
Scancell is a late-stage clinical immuno-oncology company developing off-the-shelf active immunotherapies for cancer from four proprietary technology platforms: Immunobody® (DNA-based cancer vaccines), Moditope® (peptide-based neoantigen vaccines), GlyMab® (anti-glycan antibodies), and AvidiMab® (Fc engineering). Its lead candidate, iSCIB1+, is a needle-free DNA immunotherapy combined with checkpoint inhibitors for advanced melanoma, which has reported 77% progression-free survival at 20 months versus 43% for standard ipilimumab plus nivolumab in a Phase 2 SCOPE trial, received FDA Fast Track Designation in April 2026, and is positioned to start a global Phase 3 registrational trial in Q3 2026. Secondary assets include the Modi-1 peptide vaccine in Phase 1/2 (ModiFY) for solid tumours including renal cell carcinoma, the Modi-2 pan-cancer vaccine in preclinical work, and SC134 (a GlyMab® T cell engager for small cell lung cancer) moving to IND-enabling studies. Two GlyMab® antibodies have been licensed to Genmab, providing the company's main external commercial relationship, and SCIB1/iSCIB1+ is delivered via the PharmaJet Stratis® needle-free system with UK patient access enabled by the NHS Cancer Vaccine Launch Pad.
The business model is pre-revenue and clinical-stage, with the company explicitly stating it has no current commercial products and anticipates revenue only upon regulatory approval and commercialization of iSCIB1+ and Modi-1. The monetization pathway combines (i) future product sales of iSCIB1+ and Modi-1 in melanoma and solid tumour indications; (ii) licensing royalties and milestone payments from Genmab on the GlyMab® portfolio; and (iii) potential additional antibody and platform out-licensing from a fully resourced business development function. The company is publicly listed on AIM (LSE: SCLP) with a 1,037,781,403 ordinary share base, has raised roughly £10.7 million in December 2023 and £10.3 million in December 2024 to fund the pipeline (cash runway into H2 2026), and is in advanced discussions for a reverse merger with Neuphoria Therapeutics that would provide a Nasdaq listing and additional Phase 3 financing. Customers today are clinical trial sites and research hospitals rather than paying end customers, with NHS and named UK cancer centres serving as recruitment and access channels.
Scancell firmographics
Firmographics- Name
- Scancell
- Legal name
- Scancell Holdings PLC
- Website
- https://scancell.co.uk
- Company type
- Public
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Scancell is a pre-revenue, UK-listed clinical-stage immuno-oncology company developing off-the-shelf active cancer immunotherapies (DNA, peptide, and antibody platforms) led by iSCIB1+ for advanced melanoma, licensed to Genmab on its antibody platform and advancing toward a global Phase 3.
- Ownership category
- akta.pro rank
Scancell industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
Keywords
Where Scancell is headquartered
LocationHeadquarters
- HQ city
- Nottingham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Scancell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Licensing Royalties: Scancell generates revenue through licensing agreements with partners such as Genmab for GlyMab® antibodies, with potential milestone payments and royalties on commercialized products.
- Pharmaceutical Development: Pre-revenue clinical-stage company developing cancer immunotherapies with no current commercial products. Anticipates generating revenue upon regulatory approval and commercialization of iSCIB1+ and Modi-1.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Scancell product offering
Product offeringCore offering
Scancell develops off-the-shelf active immunotherapies for cancer treatment through four proprietary platforms: Immunobody® (DNA-based vaccines), Moditope® (peptide-based vaccines), GlyMab® (anti-glycan antibodies), and AvidiMab® (Fc engineering). Its lead clinical asset iSCIB1+ is a DNA immunotherapy for advanced melanoma currently in Phase 3 development with FDA Fast Track Designation, designed for needle-free administration combined with checkpoint inhibitors.
Product overview
Scancell is a late-stage clinical immuno-oncology company developing a portfolio of off-the-shelf active immunotherapies from two proprietary technology platforms: Immunobody® (DNA-based cancer vaccines) and Moditope® (peptide-based cancer vaccines). The lead product is iSCIB1+, an Immunobody® DNA immunotherapy for advanced melanoma entering Phase III, combined with checkpoint inhibitors. The Modi-1 peptide vaccine is in Phase 2 for solid tumours. The company also has a GlyMab® antibody platform with two candidates licensed to Genmab, and an AvidiMab® Fc engineering technology. All pipeline products are designed to be off-the-shelf, patient-accessible treatments with favourable safety profiles.
Differentiator
Problem solved
Functional benefit
Brands
- GlyMab: GlyMab platform - high affinity antibodies targeting tumour specific glycans, developed by Glymab Therapeutics Ltd.
- AvidiMab
- ImmunoBody
- Moditope
Products and services
- iSCIB1+ Lead Immunobody® DNA active immunotherapy candidate for advanced melanoma. A needle-free, tumour-targeted, off-the-shelf immunotherapy entering Phase III trials, designed to generate potent and lasting immune responses when combined with checkpoint inhibitors.
- SCIB1 Earlier version of Immunobody® DNA vaccine incorporating approximately half the melanoma-specific epitopes of iSCIB1+. Demonstrated monotherapy activity in adjuvant melanoma and efficacy in combination with checkpoint inhibitors.
- Modi-1 Lead Moditope® peptide active immunotherapy targeting citrullinated peptides. An off-the-shelf, tumour-specific neoantigen therapy administered alone or with checkpoint inhibitors in solid tumours including renal cell carcinoma.
- Modi-2 Vaccine from Moditope® platform targeting stress-induced post translational modifications (siPTMs) such as homocitrullination, offering an off-the-shelf pan-cancer vaccine approach.
- SC134 Lead GlyMab® candidate being developed as a T cell engager for small cell lung cancer (SCLC), targeting FucosylGM1. Ready to move into IND-enabling studies.
Quantifiable outcome
- 77% progression-free survival at 20 months for iSCIB1+ combination therapy vs 43% for standard care (ipilimumab + nivolumab)
- +3 more outcomes
Companies that use Scancell
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Scancell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature4 records
Scancell partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship and core.
- Neuphoria Therapeutics IncflagshipAdvanced discussions for potential all-share reverse merger transaction that would enable Scancell to list on Nasdaq via reverse merger structure. Also discussing equity and debt financing for global Phase III trial of iSCIB1+.
- NHS Cancer Vaccine Launch Pad (CVLP)corePartnership with NHS enabling fast-tracked access for melanoma patients to participate in Scancell's clinical trials, accelerating patient recruitment and providing early access pathway.
- PharmaJetcoreStrategic partnership for use of PharmaJet's Stratis® IM Needle-free delivery system in the development and administration of SCIB1/iSCIB1+ cancer vaccine for advanced melanoma.
- Genmab A/ScoreGenmab has licensed two GlyMab® antibodies from Scancell and exercised option to a second commercial license agreement. Genmab is a global leader in antibody therapeutics developing these candidates for solid cancer applications.
- University of NottinghamcoreScancell was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham. Ongoing relationship for research and academic collaboration with Professor Durrant holding a personal Chair in Cancer Immunotherapy in the Department of Clinical Oncology.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Scancell competitors and assessment
Company assessmentDirect peers
- BioNTech: Develops mRNA-based cancer vaccines including BNT122 (autogene cevumeran) for melanoma and other solid tumors. Directly comparable to Scancell as a cancer vaccine developer targeting similar indications with overlapping neoantigen and active immunotherapy approaches.
- Moderna: Through its mRNA-4157/V940 personalized neoantigen vaccine (partnered with Merck), Moderna is a direct competitor in the melanoma adjuvant and advanced setting against which Scancell's iSCIB1+ will compete commercially and clinically.
- Gritstone bio: Develops neoantigen-based cancer vaccines (GRT-C901/GRT-C903) targeting shared and personalized tumor neoantigens. Direct peer to Scancell in the active immunotherapy cancer vaccine category with similar mechanism targeting MHC presentation.
- Nouscom: Private clinical-stage biotech developing off-the-shelf and personalized neoantigen cancer vaccines using viral vectors. Highly comparable to Scancell's off-the-shelf DNA/peptide vaccine platforms and clinical-stage positioning.
- CureVac: mRNA technology company developing cancer vaccines including off-the-shelf and personalized neoantigen approaches. Comparable to Scancell as a cancer vaccine developer at the intersection of mRNA and active immunotherapy.
Broad incumbents
- Immunocore: Commercial-stage UK immuno-oncology company with approved TCR-based therapy (Kimmtrak) and broader T cell receptor pipeline. Comparable to Scancell as a UK-based immuno-oncology company with overlapping T cell-targeting biology and melanoma indications.
- Adaptimmune Therapeutics: Commercial and clinical-stage TCR cell therapy company (Tecelra) developing engineered T cell therapies for solid tumors including melanoma. Comparable to Scancell as a UK-based clinical-stage immuno-oncology company targeting similar solid tumor indications.
- Bristol-Myers Squibb: Maker of ipilimumab (Yervoy) and nivolumab (Opdivo), the standard-of-care checkpoint inhibitor combination Scancell's iSCIB1+ is being tested against. The dominant incumbent in advanced melanoma CPI combinations and the principal comparator in Scancell's clinical strategy.
- Genmab A/S: Global antibody therapeutics leader and a Scancell partner (licensee of GlyMab antibodies). Comparable as a developer of antibody-based oncology therapeutics and as Scancell's principal commercial-stage antibody validation partner.
Emerging players
- Achilles Therapeutics: Clinical-stage UK biotech developing personalized neoantigen T cell therapies for solid tumors including non-small cell lung cancer and melanoma. Comparable to Scancell in cancer antigen-targeting immunotherapy with overlapping UK clinical-stage positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Scancell social profiles
Digital presenceScancell compliance and trust
Trust signalCompliance2 records
Scancell financial estimates
Financial estimateRevenue estimate
Valuation estimate
Scancell leadership team
Management profileNumber of profiles
Profiles15 records
Scancell subsidiaries and ownership
Company hierarchySubsidiaries1 record
Scancell funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Scancell M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Scancell
What does Scancell do?
Scancell develops off-the-shelf active immunotherapies for cancer treatment through four proprietary platforms: Immunobody® (DNA-based vaccines), Moditope® (peptide-based vaccines), GlyMab® (anti-glycan antibodies), and AvidiMab® (Fc engineering). Its lead clinical asset iSCIB1+ is a DNA immunotherapy for advanced melanoma currently in Phase 3 development with FDA Fast Track Designation, designed for needle-free administration combined with checkpoint inhibitors.
Is Scancell a public or private company?
Scancell is a public company. It is classified as public and is currently operating.
When was Scancell founded?
Scancell was founded in 1996. It employs 11 to 50 people.
Where is Scancell based?
Scancell is headquartered in Nottingham, United Kingdom, in the Europe region.
How does Scancell make money?
Two revenue lines are on record. Licensing Royalties are the primary driver. The others are pharmaceutical Development.
Who are Scancell's main competitors?
Direct peers on record are BioNTech, Moderna, Gritstone bio, Nouscom and CureVac. Broad incumbents are Immunocore, Adaptimmune Therapeutics, Bristol-Myers Squibb and Genmab A/S. Achilles Therapeutics is listed as an emerging player.
Does Scancell have an API?
No public API is recorded for Scancell.
What industry is Scancell in?
Scancell's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.